☆ 4.7 Article

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

MBIO (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry

Giustina De Silvestro et al.

Summary: This study analyzed data from COVID-19 inpatients in the Veneto region, Italy, and reported the results of treatment with convalescent plasma containing high-titre neutralizing antibodies. The results showed that early treatment with convalescent plasma may contribute to a favorable outcome and reduced mortality in severe COVID-19 patients, with a good safety profile.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)

Add to Collection

News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Add to Collection

Article Multidisciplinary Sciences

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19

Yogiraj Ray et al.

Summary: A clinical trial was conducted involving 80 severe COVID-19 patients to assess the effectiveness of convalescent plasma therapy (CPT). The results showed that CPT did not affect mortality rate in severe COVID-19 patients, and there were no significant clinical benefits observed.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients A Randomized Clinical Trial

Mila B. Ortigoza et al.

Summary: The randomized clinical trial did not show significant benefits of COVID-19 convalescent plasma (CCP) in hospitalized patients compared to placebo. However, exploratory analyses suggested that high-titer CCP may have benefits for early participants in the pandemic when other treatments were not in use. This indicates a heterogeneous treatment effect of CCP over time.

JAMA INTERNAL MEDICINE (2022)

Add to Collection

Article Immunology

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients

Arvind Gharbharan et al.

Summary: In this study, twenty-five B-cell-depleted patients diagnosed with COVID-19, most of whom had received anti-CD19/20 therapy, were treated with convalescent plasma containing high neutralizing antibody titers. 84% of the patients recovered, suggesting the potential therapeutic effects of this treatment in this specific population.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Respiratory System

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Leo Sekine et al.

Summary: This study investigated the effect of convalescent plasma therapy in hospitalized COVID-19 patients. The results showed that convalescent plasma therapy did not result in a higher proportion of clinical improvement compared to standard of care alone.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Review Microbiology

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes

Daniele Focosi et al.

Summary: Convalescent plasma (CP) is a frontline treatment in epidemics due to its immediate availability. The COVID-19 pandemic provided an opportunity to study the mechanisms, safety, and efficacy of CP using evidence-based medicine. However, studies have reported highly variable efficacy results for COVID-19 CP (CCP), leading to uncertainty.

CLINICAL MICROBIOLOGY REVIEWS (2022)

Add to Collection

Article Medicine, General & Internal

Early Outpatient Treatment for Covid-19 with Convalescent Plasma

D. J. Sullivan et al.

Summary: This study evaluated the efficacy and safety of COVID-19 convalescent plasma in symptomatic adults and found that receiving convalescent plasma transfusion reduced the risk of hospitalization due to COVID-19-related reasons.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

Rebecca Rockett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)

Meenu Bajpai et al.

Summary: This study compared the efficacy of COVID-19 convalescent plasma (COPLA) with standard medical therapy (SMT) in severe COVID-19 patients. The results showed that transfusing convalescent plasma with adequate antibody titres along with standard medical therapy in the first 3 days of hospitalisation can lead to better clinical outcomes.

BMJ OPEN (2022)

Add to Collection

Article Medicine, Research & Experimental

Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response

Maddalena Marconato et al.

Summary: This study provides preliminary evidence that treatment with convalescent plasma therapy, particularly with highly neutralizing plasma, is associated with faster clearance of the SARS-CoV-2 virus in hospitalized COVID-19 patients.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Add to Collection

Article Immunology

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

Gil C. De Santis et al.

Summary: A multicenter randomized trial in Brazil showed that high-dose convalescent plasma transfusion within 10 days of symptom onset did not benefit patients with severe COVID-19.

EMERGING INFECTIOUS DISEASES (2022)

Add to Collection

Article Respiratory System

Efficacy of convalescent plasma for treatment of COVID-19 in Uganda

Bruce Kirenga et al.

Summary: In this trial in Uganda, convalescent plasma therapy did not lead to beneficial virological or clinical improvements. Further trials are needed to determine subgroups of patients who may benefit from convalescent plasma in Africa.

BMJ OPEN RESPIRATORY RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial

Lise J. Estcourt et al.

Summary: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

Maria Elvira Balcells et al.

Summary: The study did not find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.

PLOS MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial*

Elliott Bennett-Guerrero et al.

Summary: This study found that administration of convalescent plasma to hospitalized patients with coronavirus disease 2019 infection did not improve outcomes, despite convalescent plasma having high neutralizing activity and increasing antibodies to severe acute respiratory syndrome coronavirus 2.

CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm

Mandana Pouladzadeh et al.

Summary: The study found that convalescent plasma has a significant impact on cytokine storm indices in severe COVID-19 patients, increasing levels of lymphocytes and IL-10 while decreasing levels of IL-6, TNF-alpha, and IFN-gamma. However, it did not have a significant effect on reducing mortality rates.

INTERNAL AND EMERGENCY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia A Randomized Clinical Trial

Francesco Menichetti et al.

Summary: The clinical trial comparing convalescent plasma (CP) plus standard therapy (ST) with ST alone in hospitalized patients with COVID-19 pneumonia showed that high-titer anti-SARS-CoV-2 CP did not reduce the progression to severe respiratory failure or death within 30 days.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Multidisciplinary Sciences

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

William N. Voss et al.

Summary: The study found that in convalescent individuals from COVID-19, the IgG antibodies primarily target epitopes outside the receptor binding domain (RBD) in the spike glycoprotein. It also revealed a protective NTD antibody and an NTD epitope that is recurrently mutated in emerging SARS-CoV-2 variants.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Manaf AlQahtani et al.

Summary: The pilot study suggests that CP therapy is safe in hospitalized COVID-19 patients, but there were no significant differences in primary and secondary outcome measures compared to standard therapy. A larger definitive study is needed for confirmation.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Biology

Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden

Karin Holm et al.

Summary: The study aimed to investigate the efficacy of convalescent plasma in hospitalized COVID-19 patients, but no significant differences were observed between the convalescent plasma group and standard of care group.

BMC RESEARCH NOTES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Philippe Begin et al.

Summary: Convalescent plasma did not reduce the risk of intubation or death at 30 days in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Arvind Gharbharan et al.

Summary: A clinical trial on 86 COVID-19 patients treated with convalescent plasma showed no overall clinical benefit, as most patients already had potent antibodies upon admission, leading to the trial being terminated prematurely.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Biology

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality

Arturo Casadevall et al.

Summary: The usage of COVID-19 convalescent plasma (CCP) therapy in the USA was high in Fall 2020 but steadily declined in Spring 2021. A strong inverse correlation between CCP usage and mortality per admission was found, with a possible association between the decline in CCP usage and excess deaths during the pandemic.

ELIFE (2021)

Add to Collection

Article Microbiology

Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals

Alena J. Markmann et al.

Summary: In this study, it was found that neutralizing antibody responses in COVID-19 convalescent individuals vary in magnitude but are durable. Higher neutralizing antibody titers are independently and significantly associated with male sex, as well as with increased age and symptom grade in male donors. Cardiometabolic comorbidities are also associated with higher antibody titers independently of sex.

MSPHERE (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia

Katharine J. Bar et al.

Summary: This study assessed the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia, showing significant benefits in clinical severity score and 28-day mortality. The results suggest that CCP may benefit select populations, especially those with comorbidities who are treated early.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19

Shanna A. Arnold Egloff et al.

Summary: The study showed that convalescent plasma (CP) is significantly associated with decreased risk of in-hospital mortality in patients with COVID-19, highlighting the importance of real-world evidence and the need for further evaluation before dismissing CP as a viable therapy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Cristina Avendano-Sola et al.

Summary: The study conducted in Spain involving 27 hospitals showed that convalescent plasma (CP) can significantly reduce the risk of progression to invasive mechanical ventilation or ECMO treatment, or death within 28 days for COVID-19 patients. However, the difference was not significant at 14 days and there was no significant improvement in overall survival.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Max R. O'Donnell et al.

Summary: This study found that the use of convalescent plasma was not associated with significant improvement in the clinical status at day 28 for severe COVID-19 patients, but it was related to significantly improved survival rates.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Yixuan J. Hou et al.

CELL (2020)

Add to Collection

Article Infectious Diseases

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Adarsh Bhimraj et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Immunology

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Lakshmanane Premkumar et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Medicine, Research & Experimental

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Timothy Devos et al.

TRIALS (2020)

Add to Collection

Article Medicine, Research & Experimental

Beyond the intention-to-treat in comparative effectiveness research

Miguel A. Hernan et al.

CLINICAL TRIALS (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.